Pharmacodynamics of glucose regulation by methylprednisolone. II. normal rats.
A physiologic pharmacodynamic model was developed to jointly describe the effects of methylprednisolone (MPL) on adrenal suppression and glycemic control in normal rats. Six groups of animals were given MPL intravenously at 0, 10 and 50 mg/kg, or by subcutaneous 7 day infusion at rates of 0, 0.1 and 0.3 mg/kg/h. Plasma concentrations of MPL, corticosterone (CST), glucose and insulin were determined at various times up to 72 h after injection and 336 h after infusion. The pharmacokinetics of MPL was described by a two-compartment model. A circadian rhythm for CST was found in untreated rats with a stress-altered baseline caused by handling, which was captured by a circadian harmonic secretion rate with an increasing mesor. All drug treatments caused CST suppression. Injection of MPL caused temporary increases in glucose over 4 h. Insulin secretion was thereby stimulated yielding a later peak around 6 h. In turn, insulin can normalize glucose. However, long-term dosing caused continuous hyperglycemia during and after infusion. Hyperinsulinemia was achieved during infusion, but diminished immediately after dosing despite the high glucose concentration. The effects of CST and MPL on glucose production were described with a competitive stimulation function. A disease progression model incorporating reduced endogenous glucose uptake/utilization was used to describe glucose metabolism under different treatments. The results exemplify the roles of endogenous and exogenous hormones in mediating glucose dynamics. The pharmacokinetic/pharmacodynamic model is valuable for quantitating diabetogenic effects of corticosteroid treatments and provides mechanistic insights into the hormonal control of the metabolic system.
Jin
Jin Y
JY
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, NY 14260, USA.
Jusko
William J
WJ
D000305:Adrenal Cortex Hormones / Q000494:pharmacology / Q000502:physiology; D000465:Algorithms; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000502:physiology; D003345:Corticosterone / Q000494:pharmacology; D003627:Data Interpretation, Statistical; D004797:Enzyme-Linked Immunosorbent Assay; D005943:Gluconeogenesis / Q000187:drug effects; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism* / Q000493:pharmacokinetics; D006706:Homeostasis / Q000187:drug effects / Q000502:physiology; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007328:Insulin / Q000097:blood; D008297:Male; D008775:Methylprednisolone / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D001786:Blood Glucose; D007328:Insulin; D005947:Glucose; D003345:Corticosterone; D008775:Methylprednisolone